Show simple item record

Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones

dc.contributor.authorSzczupak, Łukasz
dc.contributor.authorHikisz, Paweł
dc.contributor.authorKoceva-Chyla, Aneta
dc.contributor.authorKowalski, Konrad
dc.contributor.authorGuśpiel, Adam
dc.contributor.authorSolecka, Jolanta
dc.contributor.authorTherrien, Bruno
dc.contributor.authorOtt, Ingo
dc.contributor.authorOehninger, Luciano
dc.date.accessioned2021-09-15T13:35:13Z
dc.date.available2021-09-15T13:35:13Z
dc.date.issued2015
dc.identifier.citationHikisz, P.; Szczupak, Ł.; Koceva-Chyła, A.; Guśpiel, A.; Oehninger, L.; Ott, I.; Therrien, B.; Solecka, J.; Kowalski, K. Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones. Molecules 2015, 20, 19699-19718. https://doi.org/10.3390/molecules201119647pl_PL
dc.identifier.urihttp://hdl.handle.net/11089/39073
dc.description.abstractThree gold(I) complexes of alkynyl chromones were synthesized and characterized. The single-crystal X-ray structure analysis of a dinuclear compound and of a flavone derivative exhibit a typical d10 gold(I)-alkynyl linear arrangement. All complexes were evaluated as anticancer and antibacterial agents against four human cancer cell lines and four pathogenic bacterial strains. All compounds show antiproliferative activity at lower micromolar range concentrations. Complex 4 showed a broad activity profile, being more active than the reference drug auranofin against HepG2, MCF-7 and CCRF-CEM cancer cells. The cellular uptake into MCF-7 cells of the investigated complexes was measured by atomic absorption spectroscopy (AAS). These measurements showed a positive correlation between an increased cellular gold content and the incubation time of the complexes. Unexpectedly an opposite effect was observed for the most active compound. Biological assays revealed various molecular mechanisms for these compounds, comprising: (i) thioredoxin reductase (TrxR) inhibition, (ii) caspases-9 and -3 activation; (iii) DNA damaging activity and (iv) cell cycle disturbance. The gold(I) complexes were also bactericidal against Gram-positive methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) bacterial strains, while showing no activity against the Gram-negative Escherichia coli bacterial strain.pl_PL
dc.description.sponsorshipSupplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/ 20/11/19647/s1. Acknowledgments: K.K. thanks the National Science Centre in Cracow, Poland (Grant no. DEC-2011/03/B/ ST5/01015) for financial support. Author Contributions: Syntheses: Ł.S., K.K. Biology: P.H., A.K.-C. Microbiology: A.G., J.S., Atomic Absorption Spectroscopy Measurements: L.O., I.O. Research concept: K.K. X-ray structure: B.T. Writing and discussions: K.K., B.T., I.O., J.S., A.K.-C.pl_PL
dc.language.isoenpl_PL
dc.publisherMDPIpl_PL
dc.relation.ispartofseriesMolecules;20(11)
dc.rightsUznanie autorstwa 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectanticancer activitypl_PL
dc.subjectgold(I) complexespl_PL
dc.subjectferrocenepl_PL
dc.subjectTrxRpl_PL
dc.subjectcaspasespl_PL
dc.subjectantibacterial activitypl_PL
dc.titleAnticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromonespl_PL
dc.typeArticlepl_PL
dc.page.number19699-19718pl_PL
dc.contributor.authorAffiliationDepartment of Organic Chemistry, Faculty of Chemistry, University of Lodz, Tamka 12, Łódź PL-91403, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Thermobiology, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, Łódź PL-90236, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Thermobiology, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, Łódź PL-90236, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Organic Chemistry, Faculty of Chemistry, University of Lodz, Tamka 12, Łódź PL-91403, Polandpl_PL
dc.contributor.authorAffiliationLaboratory of Biologically Active Compounds, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, Warsaw PL-00791, Polandpl_PL
dc.contributor.authorAffiliationLaboratory of Biologically Active Compounds, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, Warsaw PL-00791, Polandpl_PL
dc.contributor.authorAffiliationInstitute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstr. 55, Braunschweig D-38106, Germanypl_PL
dc.contributor.authorAffiliationInstitute of Chemistry, Faculty of Science, University of Neuchatel, Avenue de Bellevaux 51, Neuchatel CH-2000, Switzerlandpl_PL
dc.identifier.eissn1420-3049
dc.referencesRosenberg, B.; Van, C.L.; Krigas, T. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode. Nature 1965, 205, 698–699pl_PL
dc.referencesCisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug; Lippert, B., Ed.; Wiley: New York, NY, USA, 1999.pl_PL
dc.referencesBerners-Price, S.J. Activating Platinum Anticancer Complexes with Visible Light. Angew. Chem. Int. Ed. 2011, 50, 804–805pl_PL
dc.referencesAllardyce, C.S.; Dyson, P.J.; Ellis, D.J.; Heath, S.I. [Ru(η 6 -p-cymene)Cl2 (pta)] (pta = 1,3,5-triaza-7- phosphatricyclo-[3.3.1.1]decane): A water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells. Chem. Commun. 2001, 15, 1396–1397pl_PL
dc.referencesPacor, S.; Zorzet, S.; Cocchietto, M.; Bacac, M.; Vadori, M.; Turrin, C.; Gava, B.; Castellarin, A.; Sava, G. Intratumoral NAMI-A Treatment Triggers Metastasis Reduction, Which Correlates to CD44 Regulation and Tumor Infiltrating Lymphocyte Recruitment. J. Pharmacol. Exp. Ther. 2004, 310, 737–744.pl_PL
dc.referencesHartinger, C.G.; Jakupec, M.A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P.J.; Keppler, B.K. KP1019, A New Redox-Active Anticancer Agent—Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. Chem. Biodivers. 2008, 5, 2140–2155.pl_PL
dc.referencesDebreczeni, J.E.; Bullock, A.N.; Atilla, G.E.; Williams, D.S.; Bregman, H.; Knapp, S.; Meggers, E. Ruthenium Half-Sandwich Complexes Bound to Protein Kinase Pim-1. Angew. Chem. Int. Ed. 2006, 45, 1580–1585pl_PL
dc.referencesVessières, A.; Top, S.; Beck, W.; Hillard, E.; Jaouen, G. Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects. Dalton Trans. 2006, 4, 529–541pl_PL
dc.referencesCitta, A.; Folda, A.; Bindoli, A.; Pigeon, P.; Top, S.; Vessières, A.; Salmain, M.; Jaouen, G.; Rigobello, M.P. Evidence for Targeting Thioredoxin Reductases with Ferrocenyl Quinone Methides. A Possible Molecular Basis for the Antiproliferative Effect of Hydroxyferrocifens on Cancer Cells. J. Med. Chem. 2014, 57, 8849–8859pl_PL
dc.referencesRubbiani, R.; Wahrig, B.; Ott, I. Historical and biochemical aspects of a seventeenth century gold-based aurum vitae recipe. J. Biol. Inorg. Chem. 2014, 19, 961–965.pl_PL
dc.referencesKoch, R. Ueber bacteriologische Forschung. Dtsch. Med. Wochenstr. 1890, 16, 756–757pl_PL
dc.referencesForestier, J. Rheumatoid arthritis and its treatment by gold salts: The results of six years’ experience. J. Lab. Clin. Med. 1935, 20, 827–840.pl_PL
dc.referencesSimon, T.M.; Kunishima, D.H.; Vibert, G.J.; Lorber, A. Screening Trial with the Coordinated Gold Compound Auranofin Using Mouse Lymphocytic Leukemia P388. Cancer Res. 1981, 41, 94–97.pl_PL
dc.referencesMirabelli, C.K.; Johnson, R.K.; Sung, C.M.; Faucette, L.; Muirhead, K.; Crooke, S.T. Evaluation of the in Vivo Antitumor Activity and in Vitro Cytotoxic Properties of Auranofin, a Coordinated Gold Compound, in Murine Tumor Models. Cancer Res. 1985, 45, 32–39.pl_PL
dc.referencesOtt, I. On the medicinal chemistry of gold complexes as anticancer drugs. Coord. Chem. Rev. 2009, 253, 1670–1681.pl_PL
dc.referencesLiu, W.; Gust, R. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chem. Soc. Rev. 2013, 42, 755–773pl_PL
dc.referencesHackenberg, F.; Tacke, M. Benzyl-substituted metallocarbene antibiotics and anticancer drugs. Dalton Trans. 2014, 43, 8144–8153.pl_PL
dc.referencesCisnetti, F.; Gautier, A. Metal/N-Heterocyclic Carbene Complexes: Opportunities for the Development of Anticancer Metallodrugs. Angew. Chem. Int. Ed. 2013, 52, 11976–11978pl_PL
dc.referencesGliši´c, B.D.; Djuran, M.I. Gold complexes as antimicrobial agents: An overview of different biological activities in relation to the oxidation state of the gold ion and the ligand structure. Dalton Trans. 2014, 43, 5950–5969pl_PL
dc.referencesTacke, M. Benzyl-substituted carbene–metal complexes: Potential for novel antibiotics and anticancer drugs? J. Organomet. Chem. 2015, 782, 17–21pl_PL
dc.referencesBagowski, C.P.; You, Y.; Scheffler, H.; Vlecken, D.H.; Schmitz, D.J.; Ott, I. Naphthalimide gold(I) phosphine complexes as anticancer metallodrugs. Dalton Trans. 2009, 48, 10799–10805.pl_PL
dc.referencesOtt, I.; Qian, X.; Xu, Y.; Vlecken, D.H.W.; Marques, I.J.; Kubutat, D.; Will, J.; Sheldrick, W.S.; Jesse, P.; Prokop, A.; et al. A Gold(I) Phosphine Complex Containing a Naphthalimide Ligand Functions as a TrxR Inhibiting Antiproliferative Agent and Angiogenesis Inhibitor. J. Med. Chem. 2009, 52, 763–770pl_PL
dc.referencesWang, V.-H.; Shih, W.-C.; Chang, H.C.; Kuo, Y.-Y.; Hung, W.-C.; Ong, T.-G.; Li, W.-S. Preparation and Characterization of Amino-Linked Heterocyclic Carbene Palladium, Gold, and Silver Complexes and Their Use as Anticancer Agents That Act by Triggering Apoptotic Cell Death. J. Med. Chem. 2011, 54, 5245–5249.pl_PL
dc.referencesRubbiani, R.; Salassa, L.; de Almeida, A.; Casini, A.; Ott, I. Cytotoxic Gold(I) N-heterocyclic Carbene Complexes with Phosphane Ligands as Potent Enzyme Inhibitors. ChemMedChem. 2014, 9, 1205–1210pl_PL
dc.referencesBertrand, B.; de Almeida, A.; van der Burgt, E.P.M.; Picquet, M.; Citta, A.; Folda, A.; Rigobello, M.P.; le Gendre, P.; Bodio, E.; Casini, A.; et al. New Gold(I) Organometallic Compounds with Biological Activity in Cancer Cells. Eur. J. Inorg. Chem. 2014, 27, 4532–4536pl_PL
dc.referencesArcau, J.; Andermark, V.; Rodrigues, M.; Giannicchi, I.; Pérez-Garcia, L.; Ott, I.; Rodríguez, L. Synthesis and Biological Activity of Gold(I) N-Heterocyclic Carbene Complexes with Long Aliphatic Side Chains. Eur. J. Inorg. Chem. 2014, 35, 6117–6125pl_PL
dc.referencesHickey, J.L.; Ruhayel, R.A.; Barnard, P.J.; Baker, M.V.; Berners-Price, S.J.; Filipovska, A. Mitochondria-Targeted Chemotherapeutics: The Rational Design of Gold(I) N-Heterocyclic Carbene Complexes That Are Selectively Toxic to Cancer Cells and Target Protein Selenols in Preference to Thiols. J. Am. Chem. Soc. 2008, 130, 12570–12571pl_PL
dc.referencesWetzel, C.; Kunz, P.C.; Kassack, M.U.; Hamacher, A.; Böhler, P.; Watjen, W.; Ott, I.; Rubbiani, R.; Spingler, B. Gold(I) complexes of water-soluble diphos-type ligands: Synthesis, anticancer activity, apoptosis and thioredoxin reductase inhibition. Dalton Trans. 2011, 40, 9212–9220pl_PL
dc.referencesBalasingham, R.G.; Williams, C.F.; Mottram, H.J.; Coogan, M.P.; Pope, S.J.A. Gold(I) Complexes Derived from Alkynyloxy-Substituted Anthraquinones: Syntheses, Luminescence, Preliminary Cytotoxicity, and Cell Imaging Studies. Organometallics 2012, 31, 5835–5843pl_PL
dc.referencesMeyer, A.; Gutiérrez, A.; Ott, I.; Rodríguez, L. Phosphine-bridged dinuclear gold(I) alkynyl complexes: Thioredoxin reductase inhibition and cytotoxicity. Inorg. Chim. Acta 2013, 398, 72–76.pl_PL
dc.referencesChui, C.-H.; Wong, R.S.-M.; Gambari, R.; Cheng, G.Y.-M.; Yuen, M.C.-W.; Chan, K.-W.; Tong, S.-W.; Tong, F.-Y.; Lau, F.-Y.; Lai, P.B.-S.; et al. Antitumor activity of diethynylfluorene derivatives of gold(I). Bioorg. Med. Chem. 2009, 17, 7872–7877pl_PL
dc.referencesSchuh, E.; Valiahdi, S.M.; Jakupec, M.A.; Keppler, B.K.; Chiba, P.; Mohr, F. Synthesis and biological studies of some gold(I) complexes containing functionalised alkynes. Dalton Trans. 2009, 48, 10841–10845pl_PL
dc.referencesVergara, E.; Cerrada, E.; Casini, A.; Zava, O.; Laguna, M.; Dyson, P.J. Antiproliferative Activity of Gold(I) Alkyne Complexes Containing Water-Soluble Phosphane Ligands. Organometallics 2010, 29, 2596–2603.pl_PL
dc.referencesMeyer, A.; Bagowski, C.P.; Kokoschka, M.; Stefanopoulou, M.; Alborzinia, H.; Can, S.; Vlecken, D.H.; Sheldrick, W.S.; Wölfl, S.; Ott, I; et al. On the Biological Properties of Alkynyl Phosphine Gold(I) Complexes. Angew. Chem. Int. Ed. 2012, 51, 8895–8899pl_PL
dc.referencesStockland, R.A.; Kohler, M.C.; Guzei, I.A.; Kastner, M.E.; Bawiec, J.A.; Labaree, D.C.; Hochberg, R.B. Organometallic Complexes Containing 17-Ethynyl-17β-hydroxyandrost-4-en-3-one and Related Ethynyl Steroids. Organometallics 2006, 25, 2475–2485.pl_PL
dc.referencesRana, B.K.; Nandy, A.; Bertolasi, V.; Bielawski, C.W.; Saha, K.D.; Dinda, J. Novel Gold(I)- and Gold(III)-N-Heterocyclic Carbene Complexes: Synthesis and Evaluation of Their Anticancer Properties. Organometallics 2014, 33, 2544–2548pl_PL
dc.referencesZou, T.; Lum, C.T.; Chui, S.-Y.; Che, C.-M. Gold(III) Complexes Containing N-Heterocyclic Carbene Ligands: Thiol “Switch-on” Fluorescent Probes and Anti-Cancer Agents. Angew. Chem. Int. Ed. 2013, 52, 2930–2933pl_PL
dc.referencesBarnard, P.J.; Berners-Price, S.J. Targeting the mitochondrial cell death pathway with gold compounds. Coord. Chem. Rev. 2007, 251, 1889–1902pl_PL
dc.referencesHolenya, P.; Can, S.; Rubbiani, R.; Alborzinia, H.; Jünger, A.; Cheng, X.; Ott, I.; Wölfl, S. Detailed analysis of pro-apoptotic signaling and metabolic adaptation triggered by a N-heterocyclic carbine-gold(I) complex. Metallomics 2014, 6, 1591–1601.pl_PL
dc.referencesPratesi, A.; Gabbiani, C.; Michelucci, E.; Ginanneschi, M.; Papini, A.M.; Rubbiani, R.; Ott, I.; Messori, L. Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation. J. Inorg. Biochem. 2014, 136, 161–169.pl_PL
dc.referencesCheng, X.; Can, P.; Alborzinia, H.; Rubbiani, R.; Ott, I.; Wölfl, S. A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells. Mol. Cancer 2014, 13, 221–236pl_PL
dc.referencesGaspar, A.; Matos, M.J.; Garrido, J.; Uriarte, E.; Borges, F. Chromone: A Valid Scaffold in Medicinal Chemistry. Chem. Rev. 2014, 9, 4960–4992.pl_PL
dc.referencesKeri, R.S.; Budagumpi, S.; Pai, R.K.; Balakrishna, R.G. Chromones as a privileged scaffold in drug discovery: A review. Eur. J. Med. Chem. 2014, 78, 340–374pl_PL
dc.referencesKurzwernhart, A.; Kandioller, W.; Bartel, C.; Bächler, S.; Trondl, R.; Mühlgassner, G.; Jakupiec, M.A.; Arion, V.B.; Marko, D.; Keppler, B.K.; et al. Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder. Chem. Commun. 2012, 48, 4839–4841pl_PL
dc.referencesKurzwernhart, A.; Kandioller, W.; Bächler, S.; Bartel, C.; Martic, S.; Buczkowska, M.; Mühlgassner, G.; Jakupiec, M.A.; Kraatz, H.-B.; Bednarski, P.J.; et al. Structure–Activity Relationships of Targeted RuII(η 6 -p-Cymene) Anticancer Complexes with Flavonol-Derived Ligands. J. Med. Chem. 2012, 55, 10512–10522pl_PL
dc.referencesMonserrat, J.-P.; Tiwari, K.N.; Quentin, L.; Pigeon, P.; Jaouen, G.; Vessières, A.; Chabot, G.G.; Hillard, E.A. Ferrocenyl flavonoid-induced morphological modifications of endothelial cells and cytotoxicity against B16 murine melanoma cells. J. Organomet. Chem. 2013, 734, 78–85.pl_PL
dc.referencesRubbiani, R.; Zehnder, T.N.; Mari, C.; Blacque, O.; Venkatesan, K.; Gasser, G. Anticancer Profile of a Series of Gold(III) (2-phenyl)pyridine Complexes. ChemMedChem 2014, 9, 2781–2790.pl_PL
dc.referencesMonserrat, J.-P.; Al-Safi, R.I.; Tiwari, K.N.; Quentin, L.; Chabot, G.G.; Vessières, A.; Jaouen, G.; Neamati, N.; Hillard, E.A. Ferrocenyl chalcone difluoridoborates inhibit HIV-1 integrase and display low activity towards cancer and endothelial cells. Bioorg. Med. Chem. Lett. 2011, 20, 6195–6197pl_PL
dc.referencesKowalski, K.; Koceva-Chyła, A.; Szczupak, Ł.; Hikisz, P.; Bernasi ´nska, J.; Rajnisz, A.; Solecka, J.; Therrien, B. Ferrocenylvinyl-flavones: Synthesis, structure, anticancer and antibacterial activity studies. J. Organomet. Chem. 2013, 741, 153–161pl_PL
dc.referencesKowalski, K.; Hikisz, P.; Szczupak, Ł.; Therrien, B.; Koceva-Chyła, A. Ferrocenyl and dicobalt hexacarbonyl chromones—New organometallics inducing oxidative stress and arresting human cancer cells in G2/M phase. Eur. J. Med. Chem. 2014, 81, 289–300pl_PL
dc.referencesKowalski, K.; Szczupak, Ł.; Oehninger, L.; Ott, I.; Hikisz, P.; Koceva-Chyła, A.; Therrien, B. Ferrocenyl derivatives of pterocarpene and coumestan: Synthesis, structure and anticancer activity studies. J. Organomet. Chem. 2014, 772, 49–59.pl_PL
dc.referencesKowalski, K.; Szczupak, Ł.; Berna´s, T.; Czerwieniec, R. Luminescent rhenium(I)chromone bioconjugate: Synthesis, photophysical properties, and confocal luminescence microscopy investigation. J. Organomet. Chem. 2015, 782, 124–130pl_PL
dc.referencesPatonay, T.; Pazurik, I.; Ábrahám, A. C-Alkynylation of Chromones by Sonogashira Reaction. Aust. J. Chem. 2013, 66, 646–654pl_PL
dc.referencesPomestchenko, I.E.; Polyansky, D.E.; Castellano, F.N. Influence of a Gold(I)-Acetylide Subunit on the Photophysics of Re(Phen)(CO)3Cl. Inorg. Chem. 2005, 44, 3412–3421.pl_PL
dc.referencesSakamoto, Y.; Moriuchi, T.; Hirao, T. Organogold(I)-uracil conjugates: Synthesis and structural characterization. J. Organomet. Chem. 2015, 782, 77–81pl_PL
dc.referencesCollins, A.R. The comet assay for DNA damage and repair. Mol. Biotechnol. 2004, 26, 249–261pl_PL
dc.referencesOrmerod, M.G.; Collins, K.L.; Rodriguez-Tarduchy, G.; Robertson, D. Apoptosis in interleukin-3-dependent haemopoietic cells: Quantification by two flow cytometric methods. J. Immunol. Methods 1992, 153, 57–65.pl_PL
dc.referencesDarzynkiewicz, Z.; Bruno, S.; Del Bino, G.; Gorczyca, W.; Hotz, M.A.; Lassota, P.; Traganos, F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992, 13, 795–808.pl_PL
dc.referencesHotz, M.A.; Gong, J.; Traganos, F.; Darzynkiewicz, Z. Flow cytometric detection of apoptosis: Comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry 1994, 15, 237–244pl_PL
dc.referencesKoceva-Chyła, A.; J ˛edrzejczak, M.; Skierski, J.; Kania, K.; Jó ´zwiak, Z. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: Relation to drug cytotoxicity and caspase-3 activation. Apoptosis 2005, 10, 1497–1514.pl_PL
dc.referencesKruidering, M.; Evan, G.I. Caspase-8 in Apoptosis: The Beginning of “The End”? IUBMB Life 2000, 50, 85–90pl_PL
dc.referencesAlenzi, F.Q.; Lotfy, M.; Wyse, R. Swords of Cell Death: Caspase Activation and Regulation. Asian Pac. J. Cancer Prev. 2010, 11, 271–280pl_PL
dc.referencesJuo, P.; Kuo, C.J.; Yuan, J.; Blenis, J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr. Biol. 1998, 8, 1001–1008pl_PL
dc.referencesMcIlwain, D.R.; Berger, T.; Mak, T.W. Caspase Functions in Cell Death and Disease. Cold Spring Harb. Perspect. Biol. 2013, 5.pl_PL
dc.referencesWolf, B.B.; Schuler, M.; Echeverri, F.; Green, D.R. Caspase-3 Is the Primary Activator of Apoptotic DNA Fragmentation via DNA Fragmentation Factor-45/Inhibitor of Caspase-activated DNase Inactivation. J. Biol. Chem. 1999, 274, 30651–30656.pl_PL
dc.referencesSheldrick, G.M. A short history of SHELX. Acta Cryst. A. 2008, 64, 112–122pl_PL
dc.referencesFarrugia, L.J. ORTEP-3 for Windows—A version of ORTEP-III with a Graphical User Interface (GUI). J. Appl. Cryst. 1997, 30, 565pl_PL
dc.referencesBruno, I.J.; Cole, J.C.; Edgington, P.R.; Kessler, M.; Macrae, C.F.; McCabe, P.; Pearson, J.; Taylor, R. New software for searching the Cambridge Structural Database and visualizing crystal structures. Acta Cryst. B 2002, 58, 389–397.pl_PL
dc.referencesRubbiani, R.; Can, S.; Kitanovic, I.; Alborzinia, H.; Stefanopoulou, M.; Kokoschka, M.; Mönchgesang, S.; Sheldrick, W.S.; Wölfl, S.; Ott, I.; et al. Comparative in Vitro Evaluation of N-Heterocyclic Carbene Gold(I) Complexes of the Benzimidazolylidene Type. J. Med. Chem. 2011, 54, 8646–8657.pl_PL
dc.referencesApproved Standard-Eighth Edition. M07-A8Method for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. CLSI: 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA, 2009; ISBN: 1-56238-689-1.pl_PL
dc.referencesKnopik-Skrocka, A.; Bielawski, J. Differences in amphotericin-B-induced hemolysis between human erythrocytes from male and female donors. Biol. Lett. 2005, 42, 49–60.pl_PL
dc.identifier.doi10.3390/molecules201119647
dc.disciplinenauki biologicznepl_PL
dc.disciplinenauki chemicznepl_PL


Files in this item

Thumbnail
Name:
license_rdf
Size:
908bytes
Format:
application/rdf+xml
View/Open
Thumbnail
Name:
molecules-20-19647-v2 (1).pdf
Size:
2.888Mb
Format:
PDF
Description:
Article
View/Open

This item appears in the following Collection(s)

Show simple item record

Uznanie autorstwa 4.0 Międzynarodowe
Except where otherwise noted, this item's license is described as Uznanie autorstwa 4.0 Międzynarodowe